GlassScriptPhysician profile
Aaron J Ackley
NPI 1699209015
$4,429.27
in general payments reported to CMS, 2019-2025
35 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.00 · 2020: $158 · 2021: $428 · 2022: $732 · 2023: $988 · 2024: $1,079 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.56 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $497.97 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $431.67 | 2021-2025 | |
| Abbvie INC. | $428.06 | 2021-2024 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $404.37 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $260.65 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.29 | 2019-2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $168.84 | 2022-2025 | |
| Glaxosmithkline, LLC. | $140.00 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $125.55 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $95.62 | 2022-2024 | |
| Edwards Lifesciences Corporation | $84.74 | 2024-2025 | |
| Exact Sciences Corporation | $80.01 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $72.78 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.84 | 2021-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.38 | 2021-2025 | Capvaxive, Dificid |
| Ardelyx, INC. | $62.34 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $57.91 | 2024-2025 | Freestyle Libre 3 |
| Seqirus USA INC | $55.81 | 2022-2025 | Flucelvax, Fluad |
| Daiichi Sankyo INC. | $47.44 | 2022 | |
| Lundbeck LLC | $44.14 | 2024-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $43.63 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $42.26 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $34.04 | 2021-2025 | Zoryve |
| Dexcom, INC. | $29.78 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $28.79 | 2024 | Veozah |
| Shield Therapeutics INC | $28.58 | 2024 | |
| Biogen, INC. | $20.06 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.81 | 2022 | |
| Corcept Therapeutics | $15.53 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2021 | |
| Verona Pharma, INC. | $14.06 | 2025 | Ohtuvayre |
| Acella Pharmaceuticals, LLC | $13.84 | 2024 | NP Thyroid 60 |
| Noven Therapeutics, LLC | $13.76 | 2023 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.